Gauging Progress Against Cervical Cancer

January is Cervical Cancer Awareness Month. Given that January was named after the Roman god Janus, whose two faces allowed him to look both backward into the old year and forward into the new one, it seemed a good time to look back at the progress we made against cervical cancer in 2018 and to look for ways to build on the progress and further reduce the incidence and mortality of the disease in the future.

Read More

FDA Expands Use of Pembrolizumab to Two Additional Cancer Types

Last week, the U.S. Food and Drug Administration (FDA) increased the number of types of cancer for which pembrolizumab (Keytruda) is a treatment option when it approved the immunotherapeutic for treating certain patients with cervical cancer and certain patients with non-Hodgkin lymphoma.

Read More